TY  - JOUR
T1  - Vaccine-induced immune responses against SARS-CoV-2 infections
A1  - Garg, Mandeep
A1  - Maralakunte, Muniraju
A1  - Kumar, Yashwant
A1  - Bhujade, Harish
A1  - Sehgal, Inder Paul
A1  - Suri, Vikas
A1  - Garg, Suruchi
Y1  - 2021///
KW  - Severe acute respiratory syndrome corona virus 2
KW  - coronavirus disease 2019
KW  - vaccine
KW  - immune response
KW  - pandemic
JF  - Exploration of Immunology
VL  - 1
IS  - 6
SP  - 356
EP  - 373
DO  - 10.37349/ei.2021.00024
UR  - https://www.explorationpub.com/Journals/ei/Article/100324
N2  - Vaccination against coronavirus disease 2019 (COVID-19) is one of the most effective tools to curb the pandemic. Multiple vaccine candidates based on different platforms are available for emergency use presently. However, in common all the vaccines target spike protein, which is a dominant immunogen of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). Adequate immunogenicity and efficacy are demonstrated by many of the vaccines in clinical phase III trials. The emergence of the new variant of concern is believed to be associated with less susceptibility to the post-infection or post-vaccination mounted immunity. It is a global concern currently threatening the progression of the vaccination drive. Nevertheless, the results of the presently available phase III clinical trials promote COVID-19 vaccination to prevent disease severity and COVID-19 related deaths. Cross-immunity towards the new variants of concern especially against the South African variant is yet to be explored and managed adequately.
ER  -